News

In clinical trials of the Alzheimer’s treatment Aduhelm (aducanumab), participants who experienced a greater reduction in brain levels of amyloid plaques — the abnormal protein clumps targeted by the treatment — tended to also experience a greater treatment benefit, in terms of cognition and functional ability, according to new…

Most amyloid-related imaging abnormalities (ARIA) occurring in Alzheimer’s patients receiving Aduhelm (aducanumab) are temporary, moderate in severity, and asymptomatic (without symptoms), according to an analysis of data from the Phase 3 ENGAGE and EMERGE trials. Most ARIA-edema (ARIA-E), or fluid accumulation in the brain, occurred within the first eight…

A new center at the Cleveland Clinic in Las Vegas, backed by broadcast journalist Maria Shriver, is focusing its efforts on preventing Alzheimer’s disease in women, who are more at risk of developing the disorder than men. Shriver has been a driving force in recognizing that Alzheimer’s disproportionately affects…

A panel of experts has crafted guidance for clinical use of Aduhelm (aducanumab), the first targeted treatment for Alzheimer’s disease recently granted accelerated approval by the U.S. Food and Drug Administration (FDA). The recommendations include criteria for determining those patients most appropriate for this once-monthly infusion treatment, and for…

Limiting air pollution may slow cognitive decline and lower the risk of dementia for older women, according to three analyses involving more than 2,000 women, ages 74 to 92, living across the U.S. “We’ve known for some time that air pollution is bad for our brains and overall health, including…

On June 7, Aduhelm (aducanumab) became the first new treatment for Alzheimer’s disease to be approved by the U.S. Food and Drug Administration (FDA) in nearly two decades, and this disorder’s first targeted therapy. Scarcely a month later, the agency took the unusual step of updating…

The National Institutes of Health (NIH) has awarded a $2-million grant to support research into the role of infections in the development of Alzheimer’s disease. The preclinical study will be conducted at The University of Texas Health Science Center at Houston (UTHealth). “If we can prove the…

AADvac1, an investigational vaccine targeting abnormal tau protein, a hallmark of Alzheimer’s disease, was found to be safe and effectively reduced the signs of neurodegeneration in patients with mild disease, according to data from the ADAMANT Phase 2 clinical trial. In a subgroup of participants with a confirmed…

A new Phase 3 trial, a collaboration between Eli Lilly and the Banner Alzheimer’s Institute, is planned to evaluate the potential of donanemab in preventing  the cognitive and functional decline related to Alzheimer’s disease. Called TRAILBLAZER-ALZ 3, the study will enroll people with “evidence” of Alzheimer’s but no clinical symptoms.

Researchers have identified new mutations in six genes that may increase the risk of developing Alzheimer’s disease. Their study involved the genetic analysis of 19 families in Utah with higher-than-normal occurrence of the disease. The scientists found relevant mutations in the genes PELI3, FCHO1, SNAP91, COX6A2, MUC16, and PIDD1.